Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice

被引:0
作者
Tomomi Kamba
Toshinari Yamasaki
Satoshi Teramukai
Noboru Shibasaki
Ryuichiro Arakaki
Hiromasa Sakamoto
Yoshiyuki Matsui
Kazutoshi Okubo
Koji Yoshimura
Osamu Ogawa
机构
[1] Kyoto University Graduate School of Medicine,Department of Urology
[2] Kyoto University Hospital,Translational Research Center
来源
International Journal of Clinical Oncology | 2014年 / 19卷
关键词
Immunotherapy; Molecular-targeted therapy; Prognosis; Renal cell carcinoma;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:505 / 515
页数:10
相关论文
共 90 条
[21]  
Mardiak J(2010)EAU guidelines on renal cell carcinoma: the 2010 update Eur Urol 58 398-406
[22]  
Motzer RJ(1999)Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 2530-2540
[23]  
Hutson TE(2009)Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 3584-3590
[24]  
Tomczak P(2005)C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy J Urol 173 52-55
[25]  
Naito S(2009)Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma Eur Urol 55 1145-1153
[26]  
Yamamoto N(2002)Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 289-296
[27]  
Takayama T(2012)C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib Int J Urol 19 908-13
[28]  
Shinohara N(2012)Novel agents and approaches for advanced renal cell carcinoma J Urol 188 707-15
[29]  
Nonomura K(undefined)undefined undefined undefined undefined-undefined
[30]  
Abe T(undefined)undefined undefined undefined undefined-undefined